RO8191
Based on 24 publication(s) in Google Scholar
RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon. RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.80%
- CAS No.: 691868-88-9
- 화학식: C14H5F6N5O
- 분자량:373.21
-
보관:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) RO8191
More- Acta Biomater. 2023 Sep 15:168:159-173. [Abstract]
- Int J Biol Macromol. 2025 Sep;321(Pt 4):146457. [Abstract]
- Phytomedicine. 2025 Jun:141:156660. [Abstract]
- Cancer Immunol Res. 2023 May 3;11(5):583-599. [Abstract]
- Cell Death Discov. 2024 Jul 28;10(1):341. [Abstract]
- Clin Transl Med. 2025 May;15(5):e70323. [Abstract]
- Microb Biotechnol. 2024 Jul;17(7):e14522. [Abstract]
- Int Immunopharmacol. 2025 May 6:157:114731. [Abstract]
- Int Immunopharmacol. 2025 Apr 22:156:114676. [Abstract]
- Int Immunopharmacol. 2024 Aug 14:141:112775. [Abstract]
- Reprod Biol Endocrinol. 2024 Aug 6;22(1):98. [Abstract]
- Poult Sci. 2024 Dec;103(12):104238. [Abstract]
- J Cell Mol Med. 2023 Oct;27(19):2922-2936. [Abstract]
- Oncol Rep. 2022 Oct;48(4):169. [Abstract]
- Appl Biochem Biotechnol. 2026 Feb;198(2):1337-1356. [Abstract]
- Curr Issues Mol Biol. 2025 May 14;47(5):361. [Abstract]
- J Biochem Mol Toxicol. 2025 Sep;39(9):e70486. [Abstract]
- Theriogenology. 2024 Mar 1:216:118-126. [Abstract]
- BMC Musculoskelet Disord. 2025 Oct 21;26(1):981. [Abstract]
- Am J Reprod Immunol. 2024 May;91(5):e13863. [Abstract]
- Virology. 2024 Feb:590:109944. [Abstract]
- Vet Sci. 2026 Mar 9;13(3):254. [Abstract]
- Graefes Arch Clin Exp Ophthalmol. 2025 Jun;263(6):1585-1596. [Abstract]
- J Mol Histol. 2025 Feb 24;56(2):95. [Abstract]
Customer Validation & Images
-
WB
-
IF
-
Flow Cytometry
-
Histological Imaging/Staining
-
Histological Imaging/Staining
Biological Activity
|
JAK1 |
RO8191 (CDM-3008) exerts antiviral activity dependent on IFNAR2/JAK1, but is independent of IFNAR1/Tyk2. RO8191, an IFNAR2 agonist, stimulates IFN signals in mice[1].
RO8191 (0.08, 0.4, 2, 10 μM; for 72 h) strongly suppresses HCV replicon activity at 72 h in a dose-dependent manner. RO8191 reduces levels of the proteins HCV NS3 and NS4A, which are localized mainly in the perinuclear region of the replicon cells[1].
RO8191 (0.08-10 μM; for 72 h) results in the disappearance of viral proteins such as NS3, NS4A/B, and NS5A/B[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 691868-88-9
-
Appearance Solid
-
분자량 373.21
-
화학식 C14H5F6N5O
-
Color Off-white to yellow
-
SMILES
FC(C1=C2C=CC3=NC(C4=NN=CO4)=CN3C2=NC(C(F)(F)F)=C1)(F)F
-
Synonyms
CDM-3008; RO4948191
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (24)
-
Journal Impact Factor
-
Most Recent
-
Acta Biomater
Matrix mechanics regulate the polarization state of bone marrow-derived neutrophils through the JAK1/STAT3 signaling pathway. [Abstract]2023 Sep 15:168:159-173. PMID: 37467837 -
Int J Biol Macromol
Lentinan attenuates histone deacetylation of SOCS1 promoter to remodel autophagy via JAK2/STAT3 pathway for the prevention of intervertebral disc degeneration. [Abstract]2025 Sep;321(Pt 4):146457. PMID: 40749910 -
Phytomedicine
Oleic acid regulates CD4+ T cells differentiation by targeting ODC1-mediated STAT5A phosphorylation in Vogt-Koyanagi-Harada disease. [Abstract]2025 Jun:141:156660. PMID: 40203473
RO8191 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jun:141:156660. [Abstract]
Protein expression and phosphorylation of CD4+ T cells treated with BSA, OA or OA+RO8191 (20 μM; 3 days) assessed by western blotting (n = 3 per group). The results showed that addition of RO8191 to OA-treated CD4+ T cells significantly reversed the down-regulation of pSTAT5A (Y694) as well as inhibition of IL-10 expression.
RO8191 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jun:141:156660. [Abstract]
Representative images of p-STAT5A (Y694) in CD4+ T cells treated with OA or OA + RO8191 (20 μM; 3 days), with quantification of p-STAT5A (Y694). Immunofluorescence showed that the nucleus localization of pSTAT5A was enhanced after addition of RO8191 in OA-treated CD4+ T cells. scale bar, 20 μm.
RO8191 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jun:141:156660. [Abstract]
Flow cytometry analysis of the percentage of Th1, Th17 and Treg cells in CD4+ T cells treated with BSA, OA, or OA+. NS, non-significance. RO8191 (20 μM; 3 days) reversed the up-regulation of Th17 and suppression of Treg cell proportion, but not the promotion of Th1 cell frequency in OA-treated CD4+ T cells.
-
Cancer Immunol Res
Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]2023 May 3;11(5):583-599. PMID: 36921097
RO8191 purchased from MedChemExpress. Usage Cited in: Cancer Immunol Res. 2023 May 3;11(5):583-599. [Abstract]
ISG-THP1 (WT) or ISG-THP1 (STING KO) cells were treated with cGAMP (0.5 μM), or RO8191 (2.5 μM) with or without various doses of podofilox for 24 h. Normalized values for ISRE luciferase activity induced by cGAMP (or RO8191) along with podofilox are shown in comparison to the activity triggered by DMSO. The results showed that podofilox only showed a tendency to enhance the ISRE-driven immune response when stimulated with RO8191, which is an agonist that directly binds to IFNAR2 and activates the expression of ISGs.
-
Cell Death Discov
2024 Jul 28;10(1):341. PMID: 39069522
RO8191 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Jul 28;10(1):341. [Abstract]
RO8191 (30 mg/kg; p.o.; once daily for 14 days). Representative haematoxylin and eosin (H&E) sections of tracheal allografts harvested on day 28 (left panel) and corresponding statistical diagram (right panel) showing the degree of stenosis.
RO8191 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Jul 28;10(1):341. [Abstract]
RO8191 (30 mg/kg; p.o.; once daily for 14 days). Representative Masson staining sections of the transplanted trachea (left panel) and corresponding statistical charts (right panel) illustrating collagen deposition.
-
Clin Transl Med
cGAS/STING signalling in macrophages aggravates obliterative bronchiolitis via an IFN-α-dependent mechanism after orthotopic tracheal transplantation in mice. [Abstract]2025 May;15(5):e70323. PMID: 40292672 -
Microb Biotechnol
Akkermansia muciniphila outer membrane protein regulates recruitment of CD8+ T cells in lung adenocarcinoma and through JAK-STAT signalling pathway. [Abstract]2024 Jul;17(7):e14522. PMID: 39016683 -
Int Immunopharmacol
2025 May 6:157:114731. PMID: 40334628 -
Int Immunopharmacol
L-Kynurenine regulates immune response in ICIs-associated myocarditis via JAK/STAT pathway. [Abstract]2025 Apr 22:156:114676. PMID: 40267722 -
Int Immunopharmacol
Obovatol inhibits proliferation, invasion and immune escape of hepatocellular carcinoma cells through modulating the JAK/STST3/PD-L1 pathway. [Abstract]2024 Aug 14:141:112775. PMID: 39146776 -
Reprod Biol Endocrinol
Liraglutide improves follicle development in polycystic ovary syndrome by inhibiting CXCL10 secretion. [Abstract]2024 Aug 6;22(1):98. PMID: 39107809 -
Poult Sci
Up-regulated Lnc BTU promotes the production of duck plague virus DNA polymerase and inhibits the activation of JAK-STAT pathway to facilitate duck plague virus replication. [Abstract]2024 Dec;103(12):104238. PMID: 39383668 -
J Cell Mol Med
MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer. [Abstract]2023 Oct;27(19):2922-2936. PMID: 37480214 -
Oncol Rep
Synergistic effects of thalidomide and cisplatin are mediated via the PI3K/AKT and JAK1/STAT3 signaling pathways in cervical cancer. [Abstract]2022 Oct;48(4):169. PMID: 35920185 -
Appl Biochem Biotechnol
DUSP7 Overexpression Suppresses Lung Adenocarcinoma Cell Proliferation, Invasion, and M2 Macrophage Polarization Through JAK2/STAT3 Pathway Inhibition. [Abstract]2026 Feb;198(2):1337-1356. PMID: 41484728 -
Curr Issues Mol Biol
2025 May 14;47(5):361. PMID: 40699760 -
J Biochem Mol Toxicol
Falcarindiol Suppresses Malignant Progression and Induces Ferroptosis in Non-Small Cell Lung Cancer by Regulating JAK/STAT3 Axis. [Abstract]2025 Sep;39(9):e70486. PMID: 40901755 -
Theriogenology
2024 Mar 1:216:118-126. PMID: 38171198 -
BMC Musculoskelet Disord
Knockdown of CLEC4D alleviates myoblast dysfunction and inflammation in sarcopenia by inhibiting the JAK/STAT pathway. [Abstract]2025 Oct 21;26(1):981. PMID: 41121007 -
Am J Reprod Immunol
NANOG regulate the JAK/STAT3 pathway to promote trophoblast cell migration and epithelial-mesenchymal transition (EMT) in hypertensive disorders of pregnancy (HDP) through protein interaction with CDK1. [Abstract]2024 May;91(5):e13863. PMID: 38796740 -
Virology
Avian coronavirus infectious bronchitis virus Beaudette strain NSP9 interacts with STAT1 and inhibits its phosphorylation to facilitate viral replication. [Abstract]2024 Feb:590:109944. PMID: 38141500 -
Vet Sci
CD4 Molecule Plays an Important Role in the Inflammatory Response Induced by Japanese Encephalitis Virus Infection. [Abstract]2026 Mar 9;13(3):254. PMID: 41893671 -
Graefes Arch Clin Exp Ophthalmol
2025 Jun;263(6):1585-1596. PMID: 39878886 -
J Mol Histol
FAM64A regulates the malignant phenotype and tumor microenvironment of non-small cell lung cancer by activating the JAK/STAT3/PDL1 axis. [Abstract]2025 Feb 24;56(2):95. PMID: 39992461
용액&용해도
DMSO : 5 mg/mL (13.40 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.5 mg/mL (1.34 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 0.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 0.5 mg/mL (1.34 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 0.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (279 KB)
-
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hideyuki Konishi, et al. An Orally Available, Small-Molecule Interferon Inhibits Viral Replication. Sci Rep. 2012;2:259. [Content Brief]
[2]. Yutaka Furutani, et al. An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes. PLoS One. 2019 Jun 12;14(6):e0216139. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6795 mL | 13.3973 mL | 26.7946 mL | 66.9864 mL |
| 5 mM | 0.5359 mL | 2.6795 mL | 5.3589 mL | 13.3973 mL | |
| 10 mM | 0.2679 mL | 1.3397 mL | 2.6795 mL | 6.6986 mL |
Powered by Bioz